Loading live market data…

Elanco Animal Health Incorporated

NYSE:ELAN

$25.54 USD

-$0.01 (-0.04%)

Volume
3.31M
Average Volume
5.78M
Market Capitalization
$12.76B
P/E Ratio
-51.31
Dividend Yield
0.00%
Price Target
$30.00
Year High
$27.72
Year Low
$13.39
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$2.16
Source Headline
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?

Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-15 13:10:25

Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement

INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.

prnewswire.com - 2026-07-08 08:00:00

Is the Options Market Predicting a Spike in Elanco Animal Health Stock?

Investors need to pay close attention to ELAN stock based on the movements in the options market lately.

zacks.com - 2026-06-30 13:40:22

Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health

New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutions INDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced plans to establish Elanco Ventures, a dedicated corporate venture capital (CVC) platform designed to support, invest and advance innovation in animal health. To be backed by a $25 million multi-year commitment, Elanco Ventures will initially focus on strategic investments in therapeutic advancements and supportive technologies across the animal health sector.

prnewswire.com - 2026-06-18 07:26:00

Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs

TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine minimizes "pokes" supporting comfortable wellness visits for pets Features proprietary PureFil™ Technology, designed to reduce vaccination reactions associated with unwanted proteini , ii , iii Product expected to begin shipping in the next 30 days INDIANAPOLIS, June 15, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) approval of TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. This milestone marks the introduction of the first and only 1/2 mL combination vaccine designed to protect dogs against both Lyme disease and leptospirosis, two increasingly prevalent threats to canine health.

prnewswire.com - 2026-06-15 08:47:00

Elanco CEO on rolling out New World screwworm vaccine: 'We're prepared'

Jeffrey Simmons, Elanco, joins 'Closing Bell Overtime' to talk producing a vaccine for the New World Screwworm infection in cattle in the U.S.

youtube.com - 2026-06-04 19:23:21

Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm

Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States  New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi  New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood  Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae  INDIANAPOLIS , June 4, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reaffirms its commitment to providing veterinarians, livestock producers, and pet owners with resources and treatment options for their animals against the escalating threat posed by New World screwworm (NWS). The fly recently reached the United States, with the first case confirmed in U.S. livestock in Texas.i  The emergence of New World screwworm in the U.S. creates a threat for veterinarians, livestock producers and pet owners that has not been seen north of the Florida Keys since the fly was eradicated from the United States more than 50 years ago.ii New World screwworm (Cochliomyia hominivorax) larvae feed on living tissue and can affect a wide range of warm-blooded animals, including livestock, companion animals, wildlife, and even humans.ii  "New World screwworm could have a devastating impact on animal health, welfare, and producer livelihoods," said Jeff Simmons, President and CEO, Elanco Animal Health.

prnewswire.com - 2026-06-04 06:26:00

Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick

On CNBC's “Mad Money Lightning Round,” Jim Cramer said about Zoetis Inc (NYSE:ZTS) that he feels "something not well there."

benzinga.com - 2026-06-03 08:05:12

New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience

INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry. According to Elanco's latest survey of 1,409 U.S. pet owners conducted May 29-31, even with rising costs across spending categories including higher gas prices, pet health and wellness remain an absolute priority for pet owners as a protected budget item.

prnewswire.com - 2026-06-03 07:26:00

Elanco Animal Health Incorporated (ELAN) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Elanco Animal Health Incorporated (ELAN) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

seekingalpha.com - 2026-06-02 18:11:51

Elanco Animal Health Incorporated (ELAN) Presents at Stifel Jaws & Paws Conference 2026 Transcript

Elanco Animal Health Incorporated (ELAN) Presents at Stifel Jaws & Paws Conference 2026 Transcript

seekingalpha.com - 2026-05-27 18:27:08

Is Elanco Animal Health Inc (ELAN) Overvalued After 5.3% Rally? GF Value Says Overvalued

On May 20, 2026, Elanco Animal Health Inc (ELAN) shares rose 5.3% today, closing at $20.85. This increase comes after a challenging month, where shares have dec

gurufocus.com - 2026-05-20 19:25:00

Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market

Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmab Starts controlling itch within 24 hours and is given as an in-clinic injection Select Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomes Meet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their journeys to itch relief Befrena is Elanco's second monoclonal antibody to launch in the U.S. pet health market, joining Trutect™, the first and only approved therapeutic solution to treat canine parvovirus and has been shown to be effective for passive immunity INDIANAPOLIS, May 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the phased launch of Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody (mAb) injection for treatment of canine allergic and atopic dermatitis. The launch comes at a key time, with a longer and more intense allergy season anticipated across the country this year.i With nearly 2 in 3 itchy dogs experiencing worse itch during allergy seasonii, Befrena expands Elanco's dermatology portfolio by offering a new treatment option that starts controlling allergic itch within 24 hours.

prnewswire.com - 2026-05-18 07:27:00

Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- What GF Score of 70 Tells Investors

On May 15, 2026, Elanco Animal Health Inc (ELAN) shares fell 8.2% today, bringing the current price to $19.96. The stock has experienced considerable volatility

gurufocus.com - 2026-05-15 21:00:00

Elanco to Participate in Upcoming Investor Conferences

INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, May 27, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the Stifel 2026 Jaws & Paws Conference at 8:00 a.m.

prnewswire.com - 2026-05-14 08:00:00

Elanco Animal Health Q1 Earnings Call Highlights

Elanco Animal Health NYSE: ELAN raised its 2026 outlook after reporting stronger-than-expected first-quarter results, citing broad-based growth across pet health and farm animal businesses, accelerating demand for new products and continued debt reduction.

marketbeat.com - 2026-05-10 03:10:41

Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript

Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 17:41:14

'WE WILL BE PREPARED': Inside efforts to stop screwworm outbreak

Elanco Animal Health CEO Jeff Simmons discusses response to screwworm outbreak concerns on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #elanco #animalhealth #jeffsimmons #screwworm #outbreak #health #animals #livestock #agriculture #farming #preparedness #biosecurity #veterinary #disease

youtube.com - 2026-05-06 16:16:29

Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) are trading higher on Wednesday, following a recent announcement regarding the approval of its products, Negasunt Powder and Tanidil, which received emergency use authorization.

benzinga.com - 2026-05-06 14:33:15

Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.4 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.37 per share a year ago.

zacks.com - 2026-05-06 08:45:42

Elanco Animal Health Reports First Quarter 2026 Results

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target First Quarter 2026 Financial Results: Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growth Reported Net Income of $57 million, Adjusted Net Income of $204 million Adjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5% Reported EPS of $0.11, Adjusted EPS of $0.40 Net leverage ratio of 3.5x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.2 billion Raising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growth Raising Adjusted EBITDA to $975 million to $1,005 million, a year-over-year increase of 10% at midpoint Raising Adjusted EPS of $1.03 to $1.09, a year-over-year increase of 13% at midpoint Improving year-end net leverage ratio target to 3.0x to 3.2x Adjusted EBITDA INDIANAPOLIS, May 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2026, provided guidance for the second quarter of 2026, and updated guidance for the full year 2026. "Elanco's strong first quarter results demonstrate the significant momentum of our innovation-led strategy," said Jeff Simmons, President and CEO of Elanco.

prnewswire.com - 2026-05-06 06:27:00

ADUS or ELAN: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Outpatient and Home Healthcare stocks have likely encountered both Addus HomeCare (ADUS) and Elanco Animal Health Incorporated (ELAN). But which of these two stocks presents investors with the better value opportunity right now?

zacks.com - 2026-04-28 12:41:12

Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock

Action Prepares Veterinarians and Livestock Producers with Prevention and Treatment Options Prior to Fly Being Detected in the U.S. Federal agencies grant emergency authorizations for New World screwworm in livestock, reinforcing Elanco's leadership in livestock health innovations   Actions underscore the commitment of the U.S. Food and Drug Administration, U.S. Environmental Protection Agency, and U.S. Department of Agriculture to act swiftly against emerging animal health threats  Early detection and immediate treatment of open wounds on livestock is critical to prevention of New World screwworm myiasis in individual animals and rapid spread of the pest An effective fly and tick control regimen is also essential, helping to avoid small bites on animals that can be an entry point for the screwworm INDIANAPOLIS, April 27, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Negasunt Powder (coumaphos, propoxur, sulfanilamide topical powder) and a Section 18 Emergency Exemption from the U.S. Environmental Protection Agency (EPA) in cooperation with the United States Department of Agriculture (USDA) for Tanidil (coumaphos, propoxur) for the prevention and treatment of New World screwworm infestations in a variety of livestock species. With confirmed cases of New World screwworm detected as close as 62 miles south of the U.S.-Mexico borderi, these authorizations ensure veterinarians and livestock producers have a ready-now treatment option for various livestock species should the fly enter the U.S. Negasunt Powder and Tanidil will be available only through the U.S. Animal Plant Health and Inspection Service (APHIS) and its National Veterinary Stockpile.

prnewswire.com - 2026-04-27 18:23:00

Elanco Animal Health Incorporated $ELAN Position Decreased by Davidson Investment Advisors

Davidson Investment Advisors decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE: ELAN) by 24.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 680,867 shares of the company's stock after selling 223,234 shares during the period.

defenseworld.net - 2026-04-20 04:27:11

Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement

INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.

prnewswire.com - 2026-04-16 08:00:00

Get ELAN Insider Trade Alerts

ELAN Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$23.00

1 analysts

Last Year

$25.40

15 analysts

All Time

$23.10

30 analysts

ELAN Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-06-18 TD Cowen Maintain Buy Buy
2026-05-07 JP Morgan Maintain Overweight Overweight
2026-05-07 Citigroup Maintain Buy Buy
2026-02-25 Keybanc Maintain Overweight Overweight
2026-02-25 Morgan Stanley Maintain Equal Weight Equal Weight
2026-02-24 Leerink Partners Maintain Outperform Outperform
2026-02-19 JP Morgan Maintain Overweight Overweight
2026-01-22 Piper Sandler Upgrade Neutral Overweight
2025-12-18 Morgan Stanley Maintain Equal Weight Equal Weight
2025-11-06 UBS Maintain Buy Buy
2025-10-20 UBS Maintain Buy Buy
2025-10-07 JP Morgan Upgrade Neutral Overweight
2025-09-24 Stifel Maintain Buy Buy
2025-08-11 Piper Sandler Maintain Neutral Neutral
2025-08-08 UBS Maintain Buy Buy
2025-07-23 UBS Maintain Buy Buy
2025-07-17 Leerink Partners Upgrade Market Perform Outperform
2025-07-02 Stifel Maintain Buy Buy
2025-06-26 William Blair Upgrade Market Perform Outperform
2025-05-19 Stifel Maintain Buy Buy
2025-05-08 Stifel Maintain Buy Buy
2025-04-14 Stifel Maintain Buy Buy
2025-03-06 Piper Sandler Maintain Neutral Neutral
2025-02-26 UBS Maintain Buy Buy
2025-02-26 Stifel Maintain Buy Buy
2025-02-26 Barclays Maintain Overweight Overweight
2025-02-26 Morgan Stanley Maintain Equal Weight Equal Weight
2025-02-21 Stifel Maintain Buy Buy
2025-01-29 Morgan Stanley Maintain Equal Weight Equal Weight
2025-01-07 Stifel Maintain Buy Buy
2024-11-08 Barclays Maintain Overweight Overweight
2024-10-28 Barclays Maintain Overweight Overweight
2024-09-23 Barclays Maintain Overweight Overweight
2024-09-19 Stifel Maintain Buy Buy
2024-09-19 Morgan Stanley Downgrade Overweight Equal Weight
2024-07-01 Piper Sandler Maintain Neutral Neutral
2024-06-28 Barclays Maintain Overweight Overweight
2024-05-13 Piper Sandler Maintain Neutral Neutral
2024-05-09 Barclays Maintain Overweight Overweight
2024-03-12 Piper Sandler Maintain Neutral Neutral
2024-02-27 Goldman Sachs Maintain Sell Sell
2024-02-27 Barclays Maintain Overweight Overweight
2024-02-27 Morgan Stanley Maintain Overweight Overweight
2024-01-17 Goldman Sachs Maintain Sell Sell
2024-01-05 Stifel Upgrade Hold Buy
2023-12-15 Morgan Stanley Upgrade Equal Weight Overweight
2023-12-07 Stifel Maintain Hold Hold
2023-11-13 Piper Sandler Maintain Neutral Neutral
2023-11-08 Morgan Stanley Maintain Equal Weight Equal Weight
2023-10-30 Stifel Maintain Hold Hold
2023-08-14 Piper Sandler Maintain Neutral Neutral
2023-08-09 Goldman Sachs Maintain Sell Sell
2023-08-08 Goldman Sachs Maintain Sell Sell
2023-04-26 Goldman Sachs Maintain Sell Sell
2023-04-25 Goldman Sachs Maintain Sell Sell
2023-04-20 Barclays Upgrade Equal Weight Overweight
2023-02-22 Barclays Maintain Equal Weight Equal Weight
2023-01-30 Morgan Stanley Maintain Equal Weight Equal Weight
2022-11-15 Morgan Stanley Maintain Equal Weight Equal Weight
2022-11-14 Piper Sandler Maintain Neutral Neutral
2022-11-09 Goldman Sachs Maintain Sell Sell
2022-10-17 JP Morgan Maintain Neutral Neutral
2022-10-07 Morgan Stanley Maintain Equal Weight Equal Weight
2022-09-12 Barclays Maintain Equal Weight Equal Weight
2022-08-18 Morgan Stanley Downgrade Overweight Equal Weight
2022-08-17 Piper Sandler Maintain Neutral Neutral
2022-08-16 JP Morgan Downgrade Overweight Neutral
2022-07-21 Goldman Sachs Downgrade Buy Sell
2022-07-18 JP Morgan Maintain Overweight Overweight
2022-07-12 Piper Sandler Maintain Neutral Neutral
2022-06-24 Stifel Maintain Hold Hold
2022-05-19 Goldman Sachs Maintain Buy Buy
2022-05-17 Morgan Stanley Maintain Overweight Overweight
2022-02-28 Barclays Maintain Equal Weight Equal Weight
2021-11-18 Morgan Stanley Maintain Overweight Overweight
2021-10-28 Stifel Downgrade Buy Hold
2021-05-11 Barclays Upgrade Underweight Equal Weight
2021-05-11 Gabelli & Co. Upgrade Hold Buy
2021-04-15 Stifel Maintain Buy Buy
2021-03-22 Gabelli & Co. Downgrade Buy Hold
2021-02-26 Credit Suisse Upgrade Neutral Outperform
2020-11-24 Morgan Stanley Maintain Overweight Overweight
2020-11-23 Morgan Stanley Maintain Overweight Overweight
2020-11-17 Citigroup Maintain Buy Buy
2020-08-20 Morgan Stanley Upgrade Equal Weight Overweight
2020-08-13 Credit Suisse Maintain Neutral Neutral
2020-08-04 Goldman Sachs Maintain Buy Buy
2020-07-27 Cleveland Research Downgrade Neutral Underperform
2020-07-20 B of A Securities Maintain Buy Buy
2020-05-15 Citigroup Maintain Buy Buy
2020-04-02 Morgan Stanley Downgrade Overweight Equal Weight
2020-01-10 Raymond James Maintain Market Perform Perform
2019-12-19 Bank of America Upgrade Neutral Buy
2019-12-19 B of A Securities Upgrade Neutral Buy
2019-11-20 UBS Maintain Neutral Neutral
2019-11-07 Morgan Stanley Upgrade Equal Weight Overweight
2019-09-23 Barclays Maintain Overweight Overweight
2019-08-26 B of A Securities Downgrade Buy Neutral
2019-08-26 Bank of America Downgrade Buy Neutral
2019-08-15 UBS Upgrade Sell Neutral
2019-05-23 Guggenheim Maintain Neutral Neutral
2019-05-10 BMO Capital Maintain Market Perform Market Perform
2019-03-18 Bank of America Upgrade Neutral Buy
2019-03-18 B of A Securities Upgrade Neutral Buy
2019-02-12 William Blair Maintain Market Perform Perform
2019-01-23 UBS Maintain Sell Sell
2019-01-15 Argus Maintain Buy Buy
2018-11-13 BMO Capital Maintain Market Perform Market Perform